Font size
click to adjust
Page tools
Search
Product Search
Recommended Links
Press Lounge
Bayer receives green light from EU authorities to use Gadovist® 1.0 in children aged two years and older
Berlin, January 27, 2012 – Bayer HealthCare successfully completed the procedure to get approval for use of the contrast medium Gadovist® 1.0 in children aged two to six years in the Europe... more
Bayer rated the most sustainable German company in its sector
One of just three chemical companies worldwide to receive Gold Class seal of quality from rating agency SAM more
Bayer HealthCare Expands Research and Manufacturing Capabilities for Interventional Franchise
Minneapolis, MN, January 19, 2012 – Bayer HealthCare announced today that it has opened a new, expanded facility for the Interventional franchise within its Medical Care’s Radiology and... more
Positive Phase III Data on Bayer’s Investigational Drug Regorafenib Show Significant Increase in Overall Survival
First presentation of data from CORRECT trial as “Late Breaking Abstract” at the 2012 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI) more
Bayer’s Xarelto® Approved in Japan for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation
Berlin, Germany, January 18, 2012 – Bayer’s once-daily oral anticoagulant Xarelto® (rivaroxaban) has been approved for the prevention of stroke and systemic embolism in patients with... more
Phase III Data of Bayer’s Regorafenib in Patients with Metastatic Colorectal Cancer to be Presented as Late Breaking Oral Presentation at 2012 ASCO-GI Congress
Late breaking abstract (LBA #385) of Phase III CORRECT study results to be presented on January 21, 2012 more
Bayer HealthCare to Share Lab Space with Start-Up Companies
Dedicated lab space-model at Bayer HealthCare U.S. Innovation Center to be called CoLaborator™ / Shared lab space will help promising life science companies get their start more